The Traderszone Network

Published in TZ Latest News 4 September, 2014 by The TZ Newswire Staff

3 Reasons Bristol-Myers Squibb’s Stock Could Fall

Bristol-Myers Squibb is a company in transition, with a host of new products under regulatory review or in clinical development. Here are three reasons why the company may falter in its plan to move past the patent cliff.

read more